Drugs and Devices

FDA approves new drugs

· On Dec. 8, the U.S. Food and Drug Administration (FDA) approved:
· Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for treatment and control of bleeding episodes in adults diagnosed with VWD. Read more.
· Kanuma (sebelipase alfa) as the first treatment for patients with lysosomal acid lipase (LAL) deficiency. Read more.

Related Articles:

Leave a Reply

You have to agree to the comment policy.


Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing